Anglo American chairman invests £97,000
A round-up of the biggest director deals today so far.
Anglo American chairman Sir John Parker has bought £97,000 worth of shares in the mining giant but this did nothing to stop the share price sliding further after last week's results and deal with Lafarge.
Sir John bought 3,000 shares at £32.38 each on Monday but the share price closed at £31.85.
Anglo American is merging its UK cement, aggregates and ready-mixed concrete business Tarmac with French giant Lafarge's UK operations - this is a 50:50 joint venture. The combined sales of the two businesses in 2010 were £1.8bn and earnings before interest, tax, depreciation and amortisation (EBITDA) was £210m.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Anglo American almost doubled profits in 2010 thanks to surging metals prices. Underlying earnings jumped to $4.98bn last year from $2.57bn in 2009 on revenue up 34% to $32.93bn. Profit before tax rose 171% to $10.93bn and underlying earnings per share of $4.13 was better than expected.
A final dividend of 40 cents a share took the total payout to 65 cents.
Top Director Buys
Reconstruction Capital II Ltd. (RC2) Director name: Mr Ion Alexander FlorescuAmount purchased: 300,000 @ €0.62 Value: €187,500
Anglo American (AAL) Director name: Sir John ParkerAmount purchased: 3,000 @ 3,238.00p Value: £97,140
AdEPT Telecom (ADT) Director name: Mr Dusan LukicAmount purchased: 25,000 @ 40.00p Value: £10,000
Top Director Sells
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
What the Employment Rights Bill means for your job
New workplace reforms are set to give employees new rights to benefits and flexible working
By Marc Shoffman Published
-
GSK share price surges after $2.2bn Zantac drug settlement
GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer
By Chris Newlands Published